Canaccord Genuity reiterates Buy rating on Exact Sciences stock ahead of study

Exact Sciences (EXAS) is a key focus for investors, with Canaccord Genuity reiterating its Buy rating and $75 price target ahead of the pivotal mid-summer BLUE-C study data readout for its blood-based colorectal cancer screening test, which will be directly compared to Guardant Health's (GH) offering. This anticipated catalyst follows the recent significant achievement of Medicare coverage for EXAS's Oncodetect molecular residual disease test, a development seen as unlocking substantial long-term growth potential. Analysts are predicting profitability for the company this year, underscoring the importance of these clinical and reimbursement milestones, with Q2 2025 financial results also due August 6.

Analysis

Exact Sciences (EXAS) is positioned at a critical juncture with two significant, yet distinct, value drivers. The most immediate catalyst is the forthcoming mid-summer data readout from its pivotal BLUE-C study for a blood-based colorectal cancer screening test. This event is highly anticipated as the results will be directly benchmarked against Guardant Health's (GH) Shield test, creating a clear competitive showdown that could significantly impact market share perception. Reinforcing a bullish outlook, Canaccord Genuity has reiterated its Buy rating and a $75 price target, suggesting substantial upside from the current $52.21 level. This sentiment is supported by upward earnings estimate revisions from three analysts and a broader price target range of $54 to $90. Beyond this near-term binary event, the company has secured a major fundamental victory with new Medicare coverage for its Oncodetect molecular residual disease test. This reimbursement decision is a key de-risking event that unlocks a long-term revenue stream and has already prompted a stock upgrade to Market Perform from Raymond James. The company's financial footing appears to be strengthening, with reported revenue growth of 11.57% and analyst forecasts predicting a transition to profitability this year, a key milestone for a growth-oriented biotech firm.

Key Decisions for Investors

• Investors should closely monitor the mid-summer BLUE-C study data release, as its outcome relative to Guardant Health's Shield test will be a primary short-term stock catalyst.
• The recent Medicare coverage for the Oncodetect test provides a significant, fundamental tailwind that may offer a degree of downside support and validates a long-term growth thesis, independent of the BLUE-C trial results.
• Given the reiterated $75 price target from Canaccord Genuity and consensus analyst expectations for profitability this year, the current valuation may present a compelling risk/reward profile for those bullish on the upcoming clinical data.
• Pay close attention to the Q2 2025 earnings call on August 6 for management's updated guidance and commentary on the commercial ramp-up of Oncodetect and the strategic implications of the BLUE-C results.